Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis

Isothermal Nucleic Acid Amplification Technology Market Analysis

Based on technology, the isothermal nucleic acid amplification technology market is categorized into Loop-mediated Isothermal Amplification (LAMP), Strand Displacement Amplification (SDA), Nucleic Acid Sequence-based Amplification (NASBA), Helicase-dependent Amplification (HDA) and others. The loop-mediated isothermal amplification (LAMP) segment accounted for around 47% market share in 2021. As loop-mediated isothermal amplification (LAMP) test is most widely used approach for amplification of DNA, RNA, and identification of genetically modified organisms.
 

Additionally, compared to PCR technology, this approach has important competitive advantages over the PCR test. The LAMP test is resistant to PCR inhibitors, making it ideal for direct sample analysis. Also, the test it is done at a constant temperature, there is no need for a thermocycler.
 

By product, the isothermal nucleic acid amplification technology market is bifurcated into instruments and reagents. Out of these, reagents segment accounted for around USD 950 million revenue size in 2021. The increasing number of diagnostic tests for infectious diseases has opened new growth opportunities.
 

Accessibility to different reagents, increased approvals of CLIA-waived tests, the continuous launch of faster, newer, and more reliable POC solutions, and rising infectious disease prevalence are also serving as important elements fueling growth avenues in the next years. Similarly, the expanding use of regents in assay development, fundamental research, and treatments, as well as repeated reagent purchases, will boost growth prospects in the forthcoming years.
 

Based on application, the industry is categorized into infectious disease, oncology, blood screening and others. Infectious disease is further divided into HIV, influenza, malaria, and tuberculosis.  The blood screening segment is projected to witness over 12% CAGR through 2022 to 2028. Blood screening test help to understand overall blood health, metabolism, liver function, mineral levels, and various other biomarkers according to the specific tests.
 

Blood screening is done for various conditions such as cancer and other infections. Different technologies are used in the blood screening such as next generation sequencing, western blot assay, enzyme-linked immunosorbent assay, nucleic acid test and others. People prefer blood screening as it provides a comprehensive data of their current state of health. It can catch potential health problems in the early stages when they can be managed most effectively. Furthermore, companies are launching several blood screenings kits for diagnosis. Such scenarios contribute towards the isothermal nucleic acid amplification technology market progression.
 

Based on end-use, the isothermal nucleic acid amplification technology (INAAT) market is divided into hospitals, diagnostic laboratories, and others. The hospital segment accounted for over USD 628 million in 2021. Hospitals are well equipped with fully automated INAAT instruments that offer quick test results as compared to laboratories.
 

Besides this, the most complex and sensitive diagnostic procedures are performed in hospitals by the skilled staff to minimize the chances of error. Furthermore, with rapid growing healthcare industry, the number of hospitals has also increased thereby fueling its isothermal nucleic acid amplification technology market growth. Owing to these factors, the demand for INAAT test in hospitals is higher than the other end-use segments.
 

North America isothermal nucleic acid amplification technology (INAAT) industry captured over 43% market share in 2021 and is poised to grow substantially during the forthcoming years. The regional growth is attributed to advances in isothermal nucleic acid amplification technology (INAAT) and a growing preference in the region for INAAT testing over traditional diagnostic procedures.
 

Surging prevalence of chronic diseases in the region will also positively influence the market expansion. For instance, according to the Centers for Disease Control and Prevention (CDC) report, in the U.S. in 2018, 1,708,921 new cancer cases were reported and 599,265 people died of cancer. For every 100,000 people, 436 new cancer cases were reported and 149 people died of cancer. In addition, the increasing number of new products launches as well as the high penetration of key market competitors in North America, are further driving the market.